- Details
- Brian Rini joins Pedro Barata to discuss the updated results of the Phase 3 LITESPARK-005 trial. The study, which led to belzutifan's approval in December 2023, compares belzutifan to everolimus in refractory clear cell RCC patients who previously received PD-1/PD-L1 and VEGF-TKI therapy. While the trial demonstrates improved progression-free survival and response rates with belzutifan, overall su...
|
- Details
- Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...
|
- Details
- Silke Gillessen joins Neeraj Agarwal to discuss the results of the STAMPEDE trial's metformin arm. The phase 3 trial evaluates the addition of metformin to androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer. While the primary endpoint of overall survival is not met, the study reveals significant improvements in metabolic parameters, including reduced w...
|
- Details
- Zachary Klaassen interviews Gautier Marcq about the LEGEND trial, a phase 1/2 study of detalimogene voraplasmid (EG-70) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Dr. Marcq discusses the trial design, which involves intravesical administration of EG-70, a non-viral gene medicine-based immunotherapy. The phase 2 study, which began in May 2023, aims to enroll 100...
|
- Details
- Zachary Klaassen hosts Sarah Howlett and Mahaz Kayani about the STAMPEDE2 platform trial, focusing on Arm N, which tests niraparib-abiraterone in metastatic hormone-sensitive prostate cancer patients with specific homologous recombination repair gene alterations. They discuss the trial's design, which randomizes patients to receive either a dual-action tablet of niraparib-abiraterone or standard A...
|
- Details
- Thomas Powles discusses the EV-302 trial data, (Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer) focusing on biomarker analyses for enfortumab vedotin (EV) plus pembrolizumab in urothelial cancer. Dr. Powles discusses the lack of discriminatory effect for PD-L1 and nectin-4 expression as biomarkers, noting that nectin-4 is nearly universally expressed in urothelial can...
|
- Details
- Shilpa Gupta interviews Thomas Powles about the NIAGARA study, which examines perioperative chemoimmunotherapy in muscle-invasive bladder cancer. Dr. Powles discusses the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in event-free and overall survival. He emphasizes the study's practice-changing potential, noting the b...
|
- Details
- Christos Kyriakopoulos discusses the phase 1/2 trial of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer. Dr. Kyriakopoulos discusses the trial design, focusing on the completed phase 1 results and ongoing phase 2 study. The phase 1 data show the combination is well-tolerated with promising efficacy, including an 88% PSA-90 response rate in evaluable patients. The t...
|
- Details
- Zachary Klaassen interviews Hiroshi Kitamura about the JCOG1019 study, examining watchful waiting versus BCG therapy in high-grade T1 bladder cancer patients with no residual tumor after second TUR. Dr. Kitamura explains the trial design and key results, highlighting that watchful waiting demonstrates non-inferiority to BCG in relapse-free survival for T1 or deeper recurrence. The study shows simi...
|
- Details
- Leslie Ballas interviews Chad Tang about the use of stereotactic body radiation therapy (SBRT) in metastatic renal cell carcinoma (RCC). Dr. Tang discusses two key approaches: treating oligometastatic disease (up to five metastatic sites) and oligoprogressive disease (one to three progressing sites). He presents data from recent studies showing SBRT's potential to delay the need for systemic thera...
|
